Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.
Actively Recruiting
Researchers are studying the use of zilovertamab vedotin ZV combined with standard treatments for participants aged 18 and older who have relapsed or refractory diffuse large B-cell lymphoma rrDLBCL. This Phase 23, randomized, open-label study aims to evaluate the safety and effectiveness of ZV with treatments like rituximab, gemcitabine, and oxaliplatin R-GemOx, or bendamustine and rituximab BR. The study has two parts Dose Confirmation and Efficacy Expansion, focusing on progression-free survival and other outcomes. Participants will receive intravenous infusions of ZV at doses ranging from 1.5 mgkg to 2.5 mgkg along with R-GemOx or BR depending on their assigned group. Treatments are given on Day 1 of repeated 21-day cycles, continuing for up to six cycles or until disease progression or discontinuation. Some participants will receive standard R-GemOx or BR treatments without ZV. Prophylactic granulocyte colony-stimulating factor G-CSF is also given at each cycle of ZV as per guidelines. During the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations over several months. Researchers will measure overall survival, progression-free survival, objective response rate, and duration of response. Participants will be closely followed for up to approximately 68 months to track safety and effectiveness outcomes throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
1-10 of 16
1